Article

Inhibition of P21-activated kinases 1 and 4 synergistically suppress the growth of pancreatic cancer by stimulating anti-tumour immunity

2024-03-11

Abstract excerpt

<h4>Background: </h4> Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal types of cancer, and KRAS oncogene occurs in over 90% of cases. P21-activated kinases (PAK), containing six members (PAK1 to 6), function downstream of KRAS. PAK1 and PAK4 play important roles in carcinogenesis, but their combinational effect remains unknown. In this study, we have determined the effect of dual inhibition of PAK...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 22ec61f0-8393-5e70-80e1-038cb1b845c4
DOI: 10.21203/rs.3.rs-3974396/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Inhibition of P21-activated kinases 1 and 4 synergistically suppress the growth of pancreatic cancer by stimulating anti-tumour immunityDOI 10.21203/rs.3.rs-3974396/v1Read

p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.Semantic proximity Read

Propionyl-CoA carboxylase subunit B regulates anti-tumor T cells in a pancreatic cancer mouse modelSemantic proximity Read

Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?Semantic proximity Read

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read

Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC ModelSemantic proximity Read

Combined MEK and STAT3 inhibition reprograms stromal inflammation to overcome immunotherapy resistance in pancreatic cancerSemantic proximity Read

ARF6-AMAP1 pathway induces pancreatic cancer cells to express immunosuppressive chemokinesSemantic proximity Read

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.Semantic proximity Read

Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancerSemantic proximity Read

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read

Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance.Semantic proximity Read

Loss of p53 tumor suppression function drives invasion and genomic instability in models of murine pancreatic cancerSemantic proximity Read